Dr. Harasaki leads Healthcare & Life Sciences (HLS) at M12.
He has 25 years of experience researching, translating, and investing in biomedical sciences. He has led or co-led over $700M in direct investments that have funded 19 immunology and oncology biopharmaceutical programs. Of these, two cancer therapies are approved in the US and EU, and eleven are currently in clinical trials.
Before joining M12, Kouki was a Partner at Andreessen Horowitz, a Menlo Park-based venture capital firm with over $19B in AUM. There, he was a senior member of the Bio Fund team – hiring and managing multiple members of the current Bio Fund team. Prior to his career in venture capital, Kouki was a Blavatnik Fellow (healthcare EIR) at Harvard and ran the AI clinical data analytics company, Medal, as COO/CFO. Medal was acquired and is now part of Datavant, a $700M+ revenue, $7B+ valuation company that hosts the largest neutral and secure health data ecosystem in the US. Prior to Medal, Kouki held Business Development (Transactions, Search & Evaluations, Head of Finance), Strategy, and Research Investigator roles at Novartis AG and Baxalta (now part of Takeda Pharmaceuticals). At Baxalta, he was responsible for developing and executing the company’s oncology strategy – leading transactions that ultimately formed the majority of its pipeline and portfolio. Baxalta was acquired for $32B in 2016 in what became the largest biopharmaceutical industry M&A transaction of that year. Kouki began his career in clinical research in the Department of Cardiothoracic Surgery at the Cleveland Clinic Foundation.
Kouki earned a Bachelor of Arts in Molecular/Cell Biology from Cornell University, a PhD in Clinical Biochemistry from the University of Cambridge (Wellcome Trust Fellow), and an MBA from Harvard Business School (Robert S. Kaplan Life Sciences Fellow). He is a board member of the Harvard Business School Healthcare Alumni Association, a member of the Alexandria Ventures Seed Capital Advisory Board, and a mentor for life science and digital health startups through Massachusetts Biotechnology Council (MassBio).